# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹2,101 Cr** (Q1 FY'26) (+7%) · **₹1,815 Cr** (Q1 FY'25) * EBITDA: ₹404 Cr (ex-other income) (+20.1% YoY) · Margin: 19.2% (+70 bps YoY) * **PAT:** **₹215 Cr** (+41%) * Gross Margin: 61.8% (+400 bps YoY, -60 bps QoQ) * **Debt & Cash:** **₹700 Cr** gross debt · **₹200 Cr** cash & equivalents (as of Jun-25) * **D&A and Interest:** **₹99 Cr** depreciation · **₹27 Cr** interest cost ## B. Revenue Growth * **Robust Top-Line Momentum:** Revenue grew at 7%, reflecting strong underlying demand and effective market execution. * **FCM Drag Quantified:** Reported domestic growth was dampened by **1 percentage point** due to FCM performance, with ex-FCM growth estimated at **~5%**. ## C. Profit Margins * **Record Profitability Achieved:** Highest-ever quarterly PAT driven by operating leverage, productivity gains, and improved business mix. * **Gross Margin Expansion Trend:** Sustained 8% gross margin reflects favorable international product mix, with management guiding for **+50 bps full-year improvement** versus prior year. ## D. Balance Sheet * **Aggressive Debt Reduction Path:** Net debt trajectory remains strong; **₹700 Cr gross debt expected to near zero by FY'26 end**, absent M&A. * **Healthy Liquidity Position:** Cash balance of **₹200 Cr** provides flexibility for capex or strategic needs while supporting deleveraging. ## E. Cash Flow * **Stable Cash Earnings Base:** Depreciation flat QoQ, supporting consistent cash flow generation from operations. * **Lower Interest Outflow:** Interest cost reduced to **₹27 Cr**, reflecting continued de-leveraging and improved capital structure. --- # 2. Product & Therapy Performance ## A. Key Figures * **Gynec Segment Growth:** ~**13%** (IQVIA data, outperforming industry) * **Orofer FCM Growth:** **Double-digit** (current quarter, prescription side) ## B. Diabetes Portfolio * **Strategic Integration:** Sanofi’s diabetes portfolio integrated into existing **three cardio-diabetes divisions**; no new MR additions planned. * **First-Line Anchor:** Acquired brands **Glycomet and Amaryl** remain key first-line therapies, providing **strong connectivity with diabetologists** to promote Vylda and future semaglutide uptake. ## C. Women’s Health Launches * **New Market Concepts:** Launched **PCOS and menopause products** last quarter; early traction positive, though **material impact delayed by market education needs**. * **Therapy-Level Outperformance:** Gynaec segment shows **strong outperformance** in India, supported by recent launches, while Cardiac is in line with industry trends. ## D. Key Growth Products * **Metabolic Diabeto Ambition:** Emcure aims to become a **key player in metabolic diabeto**, leveraging Amaryl and Cetapin within its cardio strength. * **FCM Revival:** Orofer FCM shows **double-digit prescription growth**, driven by scientific promotion and first-mover advantage; franchise now **predominantly prescription-led**. * **Blockbuster Pipeline Vision:** **Five-year product roadmap** includes **Liposomal Amphotericin B** and expansion of the **liposomal platform**, with **four key products** (including Tenecteplase and Bevacizumab) expected to ramp significantly over **18–24 months**. * **Tenecteplase Expansion:** Growing demand in **MI and stroke**; poised to become a **dominant product** in 18–24 months, pending full registration in new markets. * **Innovation Track Record:** Launched **over 11 chiral products** and pioneered **Ferrous Ascorbate** and **Ferric Carboxymaltose**, reinforcing science-led differentiation. ## E. Pipeline Progress * **Biosimilar Execution:** Successfully launched **7 biosimilars**; advancing **Asparaginase and Bevacizumab** as part of science-driven pipeline. --- # 3. Geography & Market Mix ## A. Key Figures * **Domestic Revenue:** **₹995 Cr** (+4%) * **International Revenue:** **₹1,106 Cr** (+22%) · **Emerging Markets:** **₹360 Cr** (+42%) * **Canada Revenue:** **₹342 Cr** (+4%) · **Europe Revenue:** **₹403 Cr** (+8%) ## B. Domestic Business * **Outperformance Across Therapies:** Domestic business expanded with strong momentum in Gynaecology and Cardiology, outpacing industry growth despite post-COVID volume recovery trends. * **Growth Trajectory Improving:** Volume growth recovering steadily, with full-year expectations raised to **4–5%**, supported by strategic team enhancements and new verticals. * **New Verticals on Track:** Derma and Consumer Wellness initiatives expected to add **1–2% incremental growth**, reinforcing confidence in execution capability. ## C. Emerging Markets * **High-Growth Momentum:** Emerging markets delivered robust expansion, led by strong uptake in both ARV and non-ARV portfolios across geographies. * **Regulatory Pipeline Critical:** Future growth in non-ARV segment dependent on **product registrations**, with approvals expected to drive further uplift. * **Sustained Growth Outlook:** Revenue projected to grow at **high teens to 20%** for the year, reflecting strong market traction and approval momentum. ## D. Canada Operations * **Stable Start, Strong Full-Year Outlook:** Q1 growth aligned with expectations, with **mid-teens full-year growth** anticipated, underpinned by Mantra acquisition synergies. * **Infrastructure Ready for Scale:** Core capabilities for 4–5 year expansion plan already in place, enabling sustainable growth in Canada. ## E. Europe Performance * **Double-Digit Growth Achieved:** EU operations expanded at a healthy pace, supported by a robust product pipeline and market positioning. * **Amphotericin B Rollout Timing:** UK supply active, but European ramp-up delayed until **end of current quarter** due to pending DCP approvals, with volume impact expected in second half. * **Outperformance Target Maintained:** Management remains committed to delivering **200 bps above-market growth** in competitive regions like Europe. --- # 4. R&D & Innovation ## A. New Product Launches * **Headline:** Strategic investment in innovation infrastructure and talent to enable **highly profitable, above-market growth** with a focus on execution-backed initiatives. * **Headline:** **Liposomal Amphotericin** approved in major markets, with **full commercial impact expected within 12 months** and near-term volume ramp in Europe, UK, and U.S. * **Headline:** Dual large-scale **lyophilization facilities** de-risk supply chain and support global scale-up of key sterile injectables. ## B. GLP-1 Innovations * **Headline:** India positioned for **first-wave launch** of GLP-1 agonists, with incremental innovations focused on **patient compliance** via formulation and delivery enhancements. * **Headline:** Pipeline includes **Antibody-Drug Conjugates (ADCs)** targeted for launch in **years 4 and 5**, signaling long-term platform expansion. * **Headline:** **Fully synthetic route** for GLP-1 used in India and Canada filings; **off-patent in 2026**, while semisynthetic route (fermentation) to follow in **2028**. ## C. Biosimilars & Platforms * **Headline:** **r-Asparaginase and Bevacizumab** developed for emerging markets using EU-approved references, enabling rapid regulatory roll-out in high-unmet-need regions. ## D. Regulatory Submissions * **Headline:** **Canada filing batches underway**, with submissions expected **by end-FY**, while **Asparaginase dossier submitted to DCGI** pending SEC review. * **Headline:** **Wet AMD trial completion expected by end-September**, with dossier submission to CDSCO to follow promptly. --- # 5. M&A & Strategic Partnerships ## A. Key Figures * **Sanofi Portfolio Contribution:** **₹200 Cr** annualized (8–9 months in current year) * **Manx Quarterly Revenue:** **$1–2 Mn** (expected gradual ramp-up) ## B. Sanofi Portfolio Integration * **Strategic Expansion in Metabolics:** Acquisition significantly strengthens Emcure’s footprint in metabolics, a core therapeutic pillar alongside dermatology, with integration into existing CARDIO-DIABETO division. * **No Transfer of Sales Force:** Full integration into current commercial structure underscores operational efficiency; no incremental field force acquired from Sanofi. * **Innovation-Led Growth Strategy:** R&D, multinational collaborations, and global opportunity capture (e.g., ADCs, Phase I assets) form the three-pillar roadmap for sustained differentiation. ## C. Manx & Zuventus Deals * **Near-Term Debt Impact:** Recent transactions—Manx portfolio acquisition (milestone-based) and Zuventus minority buyout—will temporarily increase gross debt. * **Zuventus Integration Status:** Minority stake acquisition completes control with **no planned operational changes** to the acute care business. * **Manx Business Trajectory:** Current contribution modest but expected to grow progressively over coming quarters. ## D. Future M&A Focus * **Portfolio Evolution Challenge:** Leadership acknowledges reliance on **me-too products** as a risk to long-term growth sustainability, prompting strategic shift toward innovation. * **Targeted Growth Levers:** Ongoing pursuit of M&A, alliances, and in-licensing focused on **India and emerging markets**, with recent expansions in **Europe and Canada** signaling international momentum. --- # 6. Pricing & Demand Risks ## A. ARV Tender & Funding Outlook * **Tender-Driven Growth:** ARV segment expansion in emerging markets remains contingent on tender wins, creating execution uncertainty despite strong competitive positioning. * **No Near-Term Funding Constraints:** As of now, no disruptions reported in ARV retendering cycle; funding agencies continue to operate on normal timelines. ## B. Pricing & Competitive Dynamics * **Institutional Pricing Pressure:** FCM faces ongoing challenges in the institutional segment due to competitive pricing, even as promoted prescriptions gain traction. ## C. Global Funding & Market Access Risks * **Limited US Tariff Impact:** Emcure’s minimal US exposure—**less than 3%** of business—insulates it from material risk despite proposed 50% tariffs on Indian exports. * **HIV Funding Volatility:** Global HIV funding shows signs of contraction, with PEPFAR and Americas government contributions to the Global Fund declining, posing demand risks for high-cost therapies. * **Lenacapavir Adoption Hinges on Funding:** Despite its clinical promise as a game changer, broad procurement of Lenacapavir depends on funding availability due to **higher costs versus standard regimens like TLD**. --- # 7. Guidance & Outlook ## A. Key Figures * **Operating Margin Target:** **23%–24%** by FY30 (from ~20%) (**+300–400 bps**) * **Capex Guidance:** **₹350 Cr/year** annualized (**₹200 Cr** growth, **₹150 Cr** maintenance) ## B. Margin Expansion Targets * **Long-Term Margin Roadmap:** Targeting **300–400 bps** operating margin expansion over 5 years via productivity gains and **favorable product/business mix shift**. * **Near-Term Margin Drivers:** FY '26 EBITDA margin expansion hinges on **scaling efficiencies**, improved field force productivity, and manufacturing utilization. * **Growth-Inflation Dynamic:** Sustained **healthy double-digit growth** outpacing inflation is critical to achieving superior margin outcomes. ## C. Growth Rate Forecasts * **Strategic Growth Pillars:** Five-year vision anchored on **innovation, partnerships, and geographic expansion**, with new leadership accelerating execution. * **Derma & Consumer Wellness:** Early-stage investments showing traction with **positive prescription trends**; full impact expected post 18–24 month gestation. * **Pipeline Catalysts:** **Asparaginase and wet AMD products** likely to gain approval within current fiscal year, potentially boosting specialty portfolio. ## D. Capex Plans * **Capex Discipline:** Annual spending set at **₹350 Cr**, with two-thirds directed toward capacity and product-specific growth initiatives. * **Cost Outlook:** Opex increases in FY '26–'27 expected to align with inflation and business growth, with no major structural cost pressures foreseen.